



# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

To, The Company Secretary, Corporate Compliance Department The National Stock Exchange of India Limited Bandra Kurla Complex, Mumbai	Date: 12 <sup>th</sup> November 2021 To, The Company Secretary Corporate Compliance Department BSE Limited Dalal Street, P.J. Tower, Mumbai
---	--

Sub: Outcome of Board Meeting held on Friday, 12<sup>th</sup> November, 2021 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref:- BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN : INE829A01014.

Dear Sir/Madam

With reference to the above captioned subject, we would like to inform that Board of Directors of the Company in their meeting held on today, i.e Friday 12<sup>th</sup> day of November 2021, has inter alia, approved the Un-audited Financial Results of the Company for the Quarter and Half year ended on 30<sup>th</sup> September, 2021 along with Segment Report, Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report thereon along with other routine businesses. *Copy of results being submitted separately.*

The Meeting of Board of Directors commenced at 3.00 p.m. and concluded at 4.30 p.m.

This is for your information and record

Thanking You,

Yours faithfully

FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED

Ramesh Shah

Chairman & Managing Director  
(DIN No. 00028819)





# BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726

Date: 12<sup>th</sup> November 2021

To,  
The Company Secretary,  
Corporate Compliance Department  
The National Stock Exchange of India Limited  
Bandra Kurla Complex, Mumbai

To,  
The Company Secretary  
Corporate Compliance Department  
BSE Limited  
Dalal Street, P.J. Tower, Mumbai

Sub: Submission of Un-Audited Financial Result for the quarter and half year ended on 30<sup>th</sup> September, 2021 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref:- BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM, ISIN : INE829A01014.

Dear Sir/Madam

Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we are hereby enclosing Un-Audited Financial Results together with Limited Review Report thereon for the quarter and half year ended on 30<sup>th</sup> September, 2021 duly approved by the Board of Directors of the Company at its meeting held today i.e. on Friday, 12<sup>th</sup> November, 2021.

Pursuant to the provisions of Regulation 33 (f) & (g) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, we have also enclosed Statement of Assets and Liabilities and Cash Flow Statement for the half year ended on 30<sup>th</sup> September 2021.

Further, above Un-Audited Financial Statements shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid results will be published in one Hindi (vernacular) and widely circulated English Newspaper. The Results shall also be uploaded on website of Stock Exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net).


You are requested to kindly take on above said results for your reference and record.

Yours Faithfully

For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah  
Chairman & Managing Director  
(DIN No. 00028819)

Encl:a/a



( Amount in Lakhs except EPS)

**Statement of Unaudited Financial Results for the quarter and Half Year ended 30th September 2021**

Sr No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2021	3 Month Ended 30/06/2021	Corresponding 3 months ended in the previous year (30/09/2020)	Year to date figures for current period ended (30/09/2021)	Year to date figures for the previous year ended (30/09/2020)	Year ended March 31 2021
I	Revenue from Operation	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
II	Other Income	1373.79	536.87	1601.86	1910.66	1831.97	3,575.04
		3.11	2.06	14.59	5.17	78.21	79.99
III	<b>Total Revenue (I + II)</b>	<b>1376.90</b>	<b>538.94</b>	<b>1616.45</b>	<b>1915.83</b>	<b>1910.18</b>	<b>3655.04</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	90.65	55.85	138.95	146.50	278.60	685.12
	(b) Purchases of stock-in-trade	1251.29	47.36	75.45	1298.66	1285.35	2834.43
	(c) Changes in inventories of finished goods, work in-progress and stock-in-trade	(38.84)	363.63	1,252.53	324.79	130.37	(276.86)
	(d) Employee benefits expense	19.94	17.41	23.25	37.35	40.00	75.16
	(e) Finance Cost	0.97	0.97	2.00	1.95	4.45	6.81
	(f) Depreciation and Amortisation Expense	10.30	10.30	10.88	20.59	21.09	41.19
	(g) Other expenses	13.53	19.32	20.69	32.85	35.96	97.29
	<b>Total expenses (IV)</b>	<b>1347.84</b>	<b>514.84</b>	<b>1523.74</b>	<b>1862.69</b>	<b>1795.80</b>	<b>3463.14</b>
V	<b>Profit/ (Loss) before exceptional items and tax (III-IV)</b>	<b>29.05</b>	<b>24.09</b>	<b>92.71</b>	<b>53.14</b>	<b>114.37</b>	<b>191.89</b>
VI	<b>Exceptional &amp; Extraordinary Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
VII	<b>Profit/ (Loss) before tax (V - VI)</b>	<b>29.05</b>	<b>24.09</b>	<b>92.71</b>	<b>53.14</b>	<b>114.37</b>	<b>191.89</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	7.79	6.70	0.00	14.49	0.00	32.75
	(2) Deferred tax Credit/(Charge)	0.00	0.00	0.00	0.00	0.00	35.01
IX	<b>Profit/(Loss) for the period from continuing operation (VII-VIII)</b>	<b>21.26</b>	<b>17.39</b>	<b>92.71</b>	<b>38.65</b>	<b>114.37</b>	<b>124.14</b>
X	<b>Profit/(Loss) from dis-continued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XI	<b>Tax expenses of discontinued operation</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XII	<b>Profit/(Loss) from dis-continued operation after tax (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit/ (Loss) for the period (IX+XII)</b>	<b>21.26</b>	<b>17.39</b>	<b>92.71</b>	<b>38.65</b>	<b>114.37</b>	<b>124.14</b>
XIV	<b>Other Comprehensive Income</b>						
	A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.63
	B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	(0.18)
	(II) Income Tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)</b>	<b>21.26</b>	<b>17.39</b>	<b>92.71</b>	<b>38.65</b>	<b>114.37</b>	<b>124.59</b>
XVI	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>
XVII	<b>Reserves (Excluding Revaluation Reserve)</b>						
XVIII	<b>Earnings per equity shares (for continuing operation):</b>						(390.50)
	(1) Basic (Rs)	0.13	0.11	0.57	0.24	0.20	0.27
	(2) Diluted (Rs)	0.13	0.11	0.57	0.24	0.20	0.27

*[Signature]*


Biofil Chemicals & Pharmaceuticals Ltd  
INDORE

XIX	Earnings Per Equity Share (for discontinued operation)						
		(1) Basic (Rs)	(2) Diluted (Rs)				
		0.00	0.00	0.00	0.00	0.00	0.00
		0.00	0.00	0.00	0.00	0.00	0.00
XX	Earnings Per Equity Share (for continuing & discontinued operation)						
		(1) Basic (Rs)	(2) Diluted (Rs)				
		0.13	0.11	0.57	0.24	0.70	0.77
		0.13	0.11	0.57	0.24	0.70	0.77


- The above unaudited results for the Quarter and half year ended Sept. 30, 2021 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 12, 2021. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
  - The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
    - Pharma Division
    - Chemicals Division.
  - The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
  - The aforesaid un-audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors.

Date : 12-11-2021  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.



RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
(DIN: 00028819)





**Biofil Chemicals and Pharmaceuticals Limited**  
Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)  
CIN L24233MP1985PLC002709  
Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718,

Reporting of Segment wise Revenue, Results and Capital Employed for quarter and half year ended 30th September 2021

S.No.	Segment Revenue	( Amount in Lakhs)					
		Quarter Ended			Half Year Ended		Year Ended
		3 Month Ended 30/09/2021	Preceeding 3 Month Ended 30/06/2021	Corresponding 3 months ended in the previous year (30/09/2020)	Year to date figures for current period ended (30/09/2021)	Year to date figures for the previous year ended (30/09/2020)	Previous Year ended March 31 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Unit						
	Chemicals Division	1,305.46	468.05	1,384.61	1,773.51	1,409.36	2,700.01
	Other	68.33	68.82	217.25	137.16	422.61	875.03
	Gross Turnover	3.08	2.06	14.59	5.14	78.21	80.45
		1,376.86	538.94	1,616.45	1,915.80	1,910.18	3,655.49
2	Segment Results						
	Pharma Unit						
	Chemicals Division	41.77	27.43	64.19	69.19	54.27	117.25
	Other	(12.27)	(2.89)	30.51	(15.16)	64.53	79.41
		0.00	0.00	0.00	0.00	0.00	0.00
	Total Segment Profit Before Tax	29.50	24.54	94.71	54.04	118.80	196.66
	Interest Income						
	Interest Expenses	0.53	0.53		1.05	0.00	2.11
	Other Unallocable Income net of Expenditure	0.97	0.97	2.00	1.94	4.43	6.42
	Profit Before Tax	29.05	24.09	92.71	53.14	114.37	192.35
	Provision for current tax						
	Item Related Earlier Year	7.79	6.70	0.00	14.49	0.00	32.75
	Profit After Tax	0.00	0.00	0.00	0.00	0.00	35.01
		21.26	17.39	92.71	38.65	114.37	124.59
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division						
	Chemicals Division	2,134.75	2,166.20	2,203.60	2,134.75	2,203.60	2,158.34
	Other	1,217.26	1,199.77	1,250.61	1,217.26	1,250.61	1,165.50
	Total (A)	0.00	0.00	0.00	0.00	0.00	0.00
		3,352.01	3,365.98	3,454.22	3,352.01	3,454.22	3,323.84
	Segment Liabilities (B)						
	Pharma Division						
	Chemicals Division	1,567.44	1,618.39	1,609.82	1,567.44	1,609.82	1,615.99
	Other	118.35	110.41	212.52	118.35	212.52	94.77
	Total (B)	0.00	0.00	0.00	0.00	0.00	0.00
		1,685.78	1,728.80	1,822.34	1,685.78	1,822.34	1,710.76
	Total Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division						
	Chemicals Division	567.32	547.81	593.78	567.32	593.78	542.35
	Other	1,098.91	1,089.37	1,038.09	1,098.91	1,038.09	1,070.73
	Total Capital Employed (Segment Assets-Segment Liabilities)	0.00	0.00	0.00	0.00	0.00	0.00
		1,666.23	1,637.18	1,631.87	1,666.23	1,631.87	1,613.09

Date : 12-11-2021  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD

RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
(DIN: 00028819)







# Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)  
CIN L24233MP1985PLC002709


Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718,  
Website: www.biofilgroup.net

## UN-AUDITED STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2021

Particulars	(Amount in Lakhs)	
	As at 30/09/2021	As at 31/03/2021
<b>A ASSETS</b>	<b>Unaudited</b>	<b>Audited</b>
<b>1 Non-current assets:</b>		
(a) Property, Plant & Equipment		
(b) Capital work in Progress	961.78	977.69
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible Assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets:		
i. Investments	-	-
ii. Trade receivables	-	-
iii. Loans	-	-
(i) Deferred tax assets (net)	-	-
(j) Other Non- Current Assets	-	-
<b>Sub-total - Non-current assets</b>	<b>-</b>	<b>-</b>
<b>2 Current assets</b>	<b>961.78</b>	<b>977.69</b>
(a) Inventories		
(b) Financial Assets:	109.87	434.46
(i) Investment	-	-
(ii) Trade receivables	-	-
(iii) Cash and cash equivalents	2635.99	1,721.79
(iv) Bank balances other than (iii) above	2.17	0.97
(v) Loans	12.53	43.08
(vi) Others (to be specified)	-	-
(c) Current Tax Asset (Net)	-	-
(d) Other Currents Assets	-	-
<b>Sub-total - Current assets</b>	<b>46.31</b>	<b>145.86</b>
<b>TOTAL - ASSETS</b>	<b>2,806.86</b>	<b>2,346.16</b>
<b>B EQUITY AND LIABILITIES</b>	<b>3,768.65</b>	<b>3,323.84</b>
<b>1 Equity</b>		
(i) Equity Share Capital	-	-
(ii) Other Equity	1627.38	1,627.38
<b>Sub-total- Equity</b>	<b>24.18</b>	<b>(14.47)</b>
<b>2 Liabilities</b>	<b>1651.56</b>	<b>1,612.91</b>
<b>Non-current Liabilities :</b>		
a. Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payable	-	-
(a) total outstanding dues of micro enterprises and small enterprises; and	-	-
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	-	-
(iii) other Financial Liabilities (other than those specified in item (b), to be specified)	-	-
b. Provisions	-	-
c. Deferred tax liabilities (net)	-	-
d. Other Non-current Liabilities	35.62	35.62
<b>Sub-total - Non-current liabilities</b>	<b>6.64</b>	<b>-</b>
<b>3 Current liabilities</b>	<b>1,693.82</b>	<b>1,648.53</b>
a. Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables :-	44.73	42.98
(a) total outstanding dues of micro enterprises and small enterprises; and	-	-
(b) total outstanding dues of creditors other than micro enterprises and small Enterprises.	-	-
(iii) other Financial Liabilities [other than those specified in item (c)]	2009.50	1,585.20
b. Other Current Liabilities	0.00	14.38
c. Provisions	0.00	-
d. Current Tax Liabilities (Net)	20.59	32.75
<b>Sub-total - Current liabilities</b>	<b>-</b>	<b>-</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,074.82</b>	<b>1,675.31</b>
	<b>3,768.65</b>	<b>3,323.84</b>

Date : 12-11-2021  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.  
RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
(DIN: 00028819)





**Biofil Chemicals and Pharmaceuticals Limited**  
Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)  
CIN L24233MP1985PLC002709  
Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718,  
Website: www.biofilgroup.net


**Statement of cash flows for the year half year ended 30th Sept 2021**

Particulars	(Amount in Lakhs)	
	HALF YEAR ENDED ON 30.09.21	HALF YEAR ENDED ON 30.09.20
	Unaudited	Unaudited
<b>Cash flow from operating activities</b>		
Profit before tax		
Adjustments to reconcile profit before tax to net cash used in operating activities	38.65	114.37
Depreciation of property, plant and equipment		
Finance cost	20.59	21.09
Impact Considered in OCI	1.95	4.45
<b>Net (gain)/ loss on derivative contracts on account of Ind AS adjustments</b>		
Provision for doubtful advances/debts		
Working capital adjustments	61.19	139.91
Increase/ (Decrease) in Inventory		
(Increase)/ Decrease in Trade Receivable	324.59	59.12
(Increase)/ Decrease in other current assets	(914.20)	748.96
Increase/ (Decrease) in trade payables	99.56	(0.42)
Increase/ (Decrease) in other financial liabilities	424.31	(890.89)
Increase/ (Decrease) in other liabilities	(14.38)	4.06
Cash generated from operations	(5.53)	0.00
Current tax assets	(24.47)	60.75
<b>Net cash flows from operating activities</b>	0.00	0.00
<b>Cash flow from investing activities</b>	(24.47)	60.75
Payment for purchase and construction of property, plant and equipment		
Proceeds from sale of property, plant and equipment	(4.69)	(13.20)
(Increase)/ Decrease in other bank balances	0.00	0.00
Interest received		
<b>Net cash flows from investing activities</b>	(4.69)	(13.20)
<b>Cash flow from financing activities</b>		
Increase/ (decrease) in Borrowings		
Deemed Investment by Holding Company	1.74	(38.99)
Finance cost	(1.95)	(4.45)
<b>Net cash flows from financing activities</b>	(0.21)	(43.44)
<b>Net increase / (decrease) in cash and cash equivalents</b>	(29.36)	4.11
Cash and cash equivalents at the beginning of the year	44.05	25.60
Cash and cash equivalents at the end of the year	14.69	29.71
<b>Increase / (Decrease) in cash and cash equivalents</b>	(29.36)	4.11

Date : 12-11-2021  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.  
INDORE  
RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
(DIN: 00028819)





**Limited Review Report**  
**(Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements))**

**To**  
**The Board of Directors**  
**Biofil Chemicals and Pharmaceuticals Limited**  
**Indore**

We have reviewed the accompanying statement of unaudited financial results of **Biofil Chemicals and Pharmaceuticals Limited** for the period ended 30th September 2021 being submitted by the Company pursuant to Regulation 33 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including relevant circular issued by the SEBI from time to time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Indian Accounting Standard 34, Interim Financial Reporting (Ind As 34) prescribed under section 133 of Companies Act 2013 and generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 2 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

**Place: Indore**  
**Date: 12.11.2021**

**For Maheshwari & Gupta**  
**Chartered Accountants**  
**FRN: 006179C**

**CA Sumil Maheshwari**  
**Partner**

**M No.403346**

**UDIN: 21403346AAAA LF3698**